For GenMark, more flu was good news in 2012

Thanks in part to a really nasty flu season, GenMark Diagnostics ($GNMK) ended 2012 with a big boost in revenue. The Carlsbad, CA, company generated $9.4 million in revenue for the 2012 fourth quarter, up substantially from $2 million in revenue over the same period a year ago. For the year, GenMark booked nearly $20.5 million in revenue, a big jump from the company's $5 million in revenue generated in 2011. GenMark's $21.9 million in net losses for the year were still high, but an improvement over nearly $24 million in net losses over the previous year. GenMark's four FDA-cleared molecular diagnostic tests focus on cystic fibrosis genotyping, respiratory viruses, thrombophilia and sensitivity to warfarin. Release

Suggested Articles

U.K.-based surgery robot developer CMR Surgical has begun rolling out its Versius platform to the NHS, completing its first procedures in Europe.

The former Fierce 15 winner’s SuperMap program was cleared to guide electrophysiologists in the treatment of stable and transient arrhythmias.

Insulet announced new agreements with Abbott and Dexcom to connect their continuous glucose monitors with its upcoming tubeless, digital insulin pump,